Addex Therapeutics Ltd. (NASDAQ:ADXN)
| Market Cap | 3.84M-65.3% |
| Revenue (ttm) | n/a-48.1% |
| Net Income | n/a-13.5% |
| EPS | n/a+25.8% |
| Shares Out | 1.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,705 |
| Open | 3.22 |
| Previous Close | 3.13 |
| Day's Range | 3.02 - 3.23 |
| 52-Week Range | 2.56 - 11.97 |
| Beta | 1.96 |
| Analysts | Buy |
| Price Target | 30.00(+861.54%) |
| Earnings Date | n/a |
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ADXN
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
$ADXN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADXN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADXN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADXN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADXN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADXN from public contracts
Source: USAspending.gov
ADXN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ADXN’s recent data — informational, not investment advice